Intravitreal bevacizumab for foveal detachment in idiopathic perifoveal telangiectasia.
OBJECTIVE
To report the use of intravitreal bevacizumab injection for the treatment of foveal detachment in idiopathic perifoveal telangiectasia (IPT).


METHODS
Prospective, interventional case series.


METHODS
Three eyes from two patients with IPT and foveal detachments were treated with a 1.25 mg/0.05 ml intravitreal injection of bevacizumab. The following variables were evaluated: visual acuity and optical coherence tomography (OCT) images.


RESULTS
The OCT images showed marked reversal of the foveal detachment after the injection, with restoration of foveal depression in all eyes. The vision of all treated eyes improved and remained unchanged up until the last follow-up visit (mean, 24 weeks).


CONCLUSIONS
A single intravitreal bevacizumab injection provides short-term improvement in visual acuity and foveal detachment associated with IPT. These findings should be followed by further studies to evaluate the long-term effects on retinal structure and function.
Maia
Otacílio Oliveira
OO
Retina and Vitreous Service, Department of Ophthalmology, University of São Paulo, São Paulo, Brazil. omaiausp@uol.com.br
Bonanomi
Maria Teresa Brizzi Chizzotti
MT
Takahashi
Walter Yukihiko
WY
Nascimento
Vinícius Paganini
VP
Takahashi
Beatriz Sayuri
BS
D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D005260:Female; D005451:Fluorescein Angiography; D005500:Follow-Up Studies; D005584:Fovea Centralis; D005654:Fundus Oculi; D006801:Humans; D007267:Injections; D008297:Male; D008875:Middle Aged; D012163:Retinal Detachment / Q000175:diagnosis / Q000188:drug therapy*; D012164:Retinal Diseases / Q000150:complications; D012171:Retinal Vessels / Q000473:pathology*; D013684:Telangiectasis / Q000150:complications*; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014822:Vitreous Body
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab